RANCHO CUCAMONGA, CA / / February 24, 2026 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the U.S. Food and ...

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) is among the 12 Most Promising Small-Cap Stocks According to Wall Street ...

RANCHO CUCAMONGA, CA / ACCESS Newswire / February 24, 2026 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the U.S. Food and Drug Administration ("FDA") has approved the Company's Abbre ...

Amphastar Pharmaceuticals (NasdaqGS:AMPH) received FDA approvals for iron sucrose and teriparatide injections. The company ...

Thank you, Paul. Good afternoon, everyone, and thank you for joining Amphastar Pharmaceuticals, Inc.'s fourth quarter 2025 earnings call. Baqsimi maintained its strong double-digit growth trajectory, ...

Q4 2025 earnings call recap: ipratropium HFA launch, 2026 revenue guidance, margins, BAQSIMI growth and pipeline updates—read now.

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Q4 2025 Earnings Call Transcript February 26, 2026 Amphastar Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $0.73 EPS, ...

Amphastar Pharmaceuticals is set to report fourth-quarter 2025 results after the market close Thursday, with investors looking for signs the generic drugmaker can translate recent regulatory wins into ...

Net revenues of $183.1 million and $719.9 million, respectively, for the three months and fiscal year ended December 31, 2025GAAP net income of $24.4 million, or $0.51 per share and $98.1 million, or ...